Daily Archives: June 4, 2018
Mon, June 4 – 10 Stories of The Day!
4 Jun, 2018 | 01:20h | UTC
#ASCO18 – Highlights from the American Society of Clinical Oncology Annual Meeting 2018
1 – #ASCO18 – Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer – New England Journal of Medicine (free)
Commentaries: 2018 ASCO: TAILORx: Most Women With Early-Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test – The ASCO Post (free) AND Many breast cancer patients can skip chemo, big study finds – STAT (free) AND Many women with early-stage breast cancer can skip chemotherapy: study – Reuters (free) AND For Some Breast Cancer Patients, The Chemo Decision Just Got Easier – NPR (free) AND Breast cancer: Test means fewer women will need chemotherapy – BBC (free) AND Good News for Women With Breast Cancer: Many Don’t Need Chemo – The New York Times (10 articles per month are free)
Commentary: Increase in lifestyle-related cancers over past decade spotlights critical need for prevention – Institute for Health Metrics and Evaluation (free)
3 – #ASCO18 – Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma – New England Journal of Medicine (free)
Editorial: Cytoreductive Nephrectomy — Patient Selection Is Key (free)
Commentaries: 2018 ASCO: Carmena Trial Compares Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone in Metastatic RCC – The ASCO Post (free) AND In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care – Medscape (free registration required)
4 – #ASCO18 – Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study (link to abstract)
Commentaries: 2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More – The ASCO Post (free) AND ‘End of an Era’ for Chemo in Non-Small Cell Lung Cancer – Medscape (free registration required)
5 – #ASCO18 – Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia – New England Journal of Medicine (free)
Commentary: Ibrutinib/Rituximab Improves PFS in Waldenström’s Macroglobulinemia – ASCO Daily News (free)
6 – #ASCO18 – Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016 – Cancer Spectrum (free) (via @oncology_bg see Tweet)
7 – #ASCO18 – Editorial: Marketing personalized cancer treatments requires careful language – Nature (free)
Related: What Precisely Is Precision Oncology—and Will It Work? – The ASCO Post (free) AND Hope and hype around cancer immunotherapy – CNN (free)
“Therapies tailored to individual tumors must not be oversold”.
8 – #ASCO18 – 2018 ASCO: Low-Dose Maintenance Chemotherapy in Rhabdomyosarcoma – The ASCO Post (free)
9 – #ASCO18 – 2018 ASCO: Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer – The ASCO Post (free)
Commentary: Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer – Forbes (free)
10 – #ASCO18 – Antibiotics greatly reduce effectiveness of cancer treatment – study – The Guardian (free) AND Antibiotics HALVE life expectancy of cancer sufferers, NHS medics reveal in world first at US conference – Daily Maily (free)